CompletedPhase 2NCT04647890

Effects of FT011 in Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Certa Therapeutics
Principal Investigator
Darren Kelly, PhD
Certa Therapeutics Pty Ltd
Intervention
FT011(drug)
Enrollment
30 enrolled
Eligibility
18-75 years · All sexes
Timeline
20212022

Study locations (10)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04647890 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials